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Abstract
Along with rising numbers of patients with metabolic syndrome, the prevalence of nonalcoholic fatty liver disease
(NAFLD) has increased in proportion with the obesity epidemic. While there are no established treatments for
NAFLD, current research is targeting new molecular mechanisms that underlie NAFLD and associated metabolic
disorders. This review discusses some of these emerging molecular mechanisms and their therapeutic implications
for the treatment of NAFLD. The basic research that has identified potential molecular targets for pharmacotherapy
will be outlined.
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The prevalence of obesity is increasing worldwide. While
there are no established treatments for NAFLD, however
current research is targeting new molecular mechanisms
that underlie NAFLD and associated metabolic disorders.
Nuclear transcription factors: PXR and FXR
Studies in mice have shown that the Pregnane X Recep-
tor (PXR), Farnesoid X Receptor (FXR), and Forkhead
O1 are implicated in hepatic steatosis and in lipid and
glucose metabolism [1]. It is accepted that nuclear tran-
scription factors are major regulators of the metabolism
of lipid and glucose but the specific pathways and inter-
relationships are still being investigated. PXR was ini-
tially found to activate transcription of steroid-inducible
genes by forming a heterodimer with RXR and binding
to PXR response elements in response to a number of
different steroid precursors and metabolites as well as
other both natural and synthetic compounds [2]. Many
studies have demonstrated that PXR plays an important
role in the clearance and elimination of toxic products
of metabolism [3], however it has become clear that
PXR also plays an important role in lipid metabolism as
it was shown that PXR could increase fatty acid uptake
by directly increasing the expression of the membrane
bound fatty acid transporter (FAT, CD36) [4] PXR trans-
genic mice demonstrated hepatic steatosis [1]. Further
studies have shown that PXR exerts its effect on lipid
metabolism through several distinct mechanisms. In
addition to its first known role in increasing fatty acid
uptake into hepatocytes, PXR is also able to increase
lipogenesis while also down regulating fatty acid beta
oxidation. PXR’s ability to increase lipogenesis is due to
enhanced transcription of stearoyl-CoA desaturase, fatty
acid elongase, fatty acid synthase, and ATP citrate lyase
[5]. These effects are largely due to the interaction of
PXR with S14, which is response to various nutrient and
hormonal signals [5]. The ability of PXR to downregulate
fatty acid beta oxidation is largely due to its ability to
impair signaling through the forkhead transcription fac-
tor Foxa2. Foxa2 induces transcription of genes neces-
sary for fatty acid oxidation and ketogenesis and it is
rendered inactive in the cytoplasm by insulin [6]. Foxa2
mediates the upregulation of carnitine palmitoyltransfer-
ase (Cpt1a, involved in beta-oxidation) and 3-hydroxy-3-
methylglutarate-CoA synthase 2 (Hmgcs2, involved in
ketogenesis), and PXR is able to directly bind Foxa2 and
impair its ability to upregulate these genes [7]. Addition-
ally, PXR has been shown to interact with the forkhead
box-containing protein O subfamily (FOXO1). FOXO1
regulates the expression of several enzymes involved in
gluconeogenesis and FOXO1 mRNA levels have been
shown to correlate with the severity of NASH [8]. FOXO1
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can act as a coactivator of PXR mediated transcription,
however, their interaction is complex, and under the pres-
ence of the appropriate activator, PXR can act as a core-
pressor of FOXO1 mediated transcription [9].
Farnesoid X receptor (FXR) was originally described as a
farnesol-activated receptor and has long been known for
its function as a bile acid sensor in enterohepatic tissues
[10]. FXR has emerged in recent years as a master regula-
tor of lipid and glucose homeostasis in the liver and of in-
flammatory processes at hepatic and extrahepatic sites, and
a number of synthetic FXR agonists are being tested for
the treatment of different hepatic and metabolic disorders
[11,12] given the ability of FXR to antagonize inflammatory
and fibrogenic processes. Two FXR genes have been identi-
fied, FXRα and FXRβ. FXRα is expressed mainly in the
liver, intestines, kidney, and adrenal glands, and at much
lower levels in adipose tissues. FXRβ is a lanosterol sensor
that encodes a functional protein in rodents but not in
humans [13]. FXR is an obligate partner of the 9-cis-
retinoic acid receptor RXR (retinoid X receptor). The rele-
vance of FXR to hepatic physiology and disease became
apparent from the observation that FXR-knockout mice on
a high-fat diet exhibit hyperlipidemia and massive hepatic
steatosis, as well as necroinflammation and fibrogenesis
[14,15]. Importantly, a high fat diet led to macrosteatosis
without inflammation in the livers of LDL receptor knock-
out mice whereas the livers of mice double-knockout
(LDLR−/− and FXR−/−) mice showed necroinflammation
and increased hepatic levels of tumor necrosis factor-α,
intercellular adhesion molecule-1, transforming growth
factor (TGF)–β, procollagen 1α1, and collagen, suggesting
FXR may prevent progression of simple steatosis to NASH.
FXR induces expression of genes that promote triglyceride
clearance and mitochondrial fatty acid β-oxidation, as well
as suppression of lipogenic gene transcription [16]. FXR
also upregulates the genes encoding apolipoprotein C-II
(apoC-II) and very-low-density lipoprotein receptor, there-
fore enhancing triglyceride-rich lipoprotein clearance,
while apoA-I gene expression is suppressed [17]. Synthetic
FXR agonists decrease gluconeogenesis in mice fed a high-
fat diet by reducing the expression and activity of PEPCK,
G6Pase, and fructose-1,6-biphosphatase, and by enhan-
cing insulin signaling through insulin receptor substrate-1
(IRS-1) phosphorylation [18,19]. FXR also appears to
antagonize hepatic inflammatory and fibrogenetic pro-
cesses. Another hepatic protective mechanism of FXR acti-
vation has been shown to be maintenance of gut integrity
against gut-derived endotoxins through induction of anti-
bacterial factors such as angiogenin, iNOS, and interleukin
(IL)–18 [20].
PPARs, RXR and FGF21
Three distinct members of the peroxisome proliferator
activated receptor (PPAR) sub-family each encoded by a
distinct gene have been identified and well characterized.
PPARα (NR1C1) is highly expressed in liver, kidney, and
muscle. PPARγ (NR1C3) is enriched in adipose tissue
and PPARβ/δ (NR1C2; referred to as PPARδ in this
review) appears to be ubiquitously expressed. All three
PPARs bind to DNA as heterodimers with retinoid X
receptors (RXR; NR2B sub-group) and bind preferentially
to direct repeats of the nuclear receptor half site AGGTCA
separated by 1 nucleotide (DR1). Each sub-type appears to
have unique functions and PPARα and PPARγ are the tar-
gets of the fibrate and thiazolidinedione (TZD) classes of
drugs respectively.
Studies in vitro and in vivo have demonstrated that
PPARα directly regulates a network of genes encoding
the proteins required for the uptake of fatty acids, en-
zymes required of the oxidation of fatty acids, and en-
zymes required for ketogenesis by binding to control
regions in the promoter of these genes. Thus, activation
of PPARα promotes the utilization of fat as an energy
source. Mice lacking PPARα accumulate triglycerides in
the liver and become hypoglycemic during fasting or
starvation. Recent studies indicate that fibroblast growth
factor 21 (FGF21) functions as an endocrine hormone
that mediates many of the effects of PPARα. The gene
encoding FGF21is directly induced by PPARα in re-
sponse to fasting via a binding site in the promoter.
FGF21 in turn stimulates lipolysis in adipose tissue and
ketogenesis in the liver. In vitro studies have demon-
strated that fatty acids can bind to PPARα and function
as ligands. More recently, affinity purification of PPARα
from mouse livers followed by mass spectrometery iden-
tified 1-palmityol-2-oleoyl-sn-glycerol-3-phosphocholine
(16:0/18:1-GPC) as a selective PPARα agonist [21]. Inter-
estingly, the production of 16:0/18:1-GPC requires the
activity of fatty acid synthase (FAS) suggesting that
PPARα-dependent fat oxidation serves as a regulatory
mechanism to ensure that fatty acids levels stay within an
optimum range. Taken together PPARα appears to func-
tion as a sensor of the fed/starved state.
PPARγ is a master transcriptional regulator of adipo-
genesis and plays an important role in the process of
lipid storage [22]. Thus PPARα and PPARγ have oppos-
ing functions in the regulation of fat metabolism; PPARα
promotes utilization while activation of PPARγ promotes
storage. Indeed, it has been suggested that PPARγ’s role
in the activation of lipogenic genes may contribute to the
development of steatosis, as increased PPARγ expression
has been found in steatotic livers. Nevertheless, several
studies have shown that overexpression of PPARγ can pre-
vent the progression of hepatic steatosis in mouse models
and treatment with the PPARγ agonist rosiglitazone has
been shown to have similar effects. The protective effects
of PPARγ could be due to increased insulin sensitivity in
adipose tissue and skeletal muscle leading to decreased
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FFA deposition in the liver. Adiponectin has also been
shown to be increased by PPARγ which also contributes
to insulin sensitivity as well as up-regulating PPARα ex-
pression, which leads to further hepatic fatty acid oxida-
tion. Furthermore, PPARγ expression has been shown to
have anti-inflammatory and anti-fibrotic effects in stellate
cells, macrophages, and epithelial cells.
A number of naturally occurring fatty acids and prosta-
noids have been shown to act as PPARγ agonists, however,
perhaps most importantly was the identification that the
TZD class of insulin sensitizing drugs including rosiglita-
zone (Avandia) and pioglitazone (Actos) are PPARγ ago-
nists. Fatty acid accumulation in insulin sensitive tissues
such as liver and skeletal muscle has been shown to pro-
mote insulin resistance. Activation of PPARγ in adipose
has been proposed to increase the number of adipocytes
and promote the relocalization and storage of fat in adi-
pose tissue, protecting peripheral tissues from lipotoxicity.
Consistent with this idea is the observation that selective
knockout of PPARγ in adipose tissue eliminates the thera-
peutic activity of TZDs in mice and that a common side
effect of TZD in treatment in humans is weight gain due
to an increase in adipose mass. The TZDs have proven to
be effective drugs for improving insulin sensitivity and
treating type II diabetes. Nevertheless, they are not with-
out problems. Troglitazone, the first TZD to be used in the
clinic, was taken off the market because of cases of drug-
induced liver damage. Additionally recent meta-analyses
have indicated that treatment with rosiglitazone is asso-
ciated with increased risk of myocardial infarction and
deaths due to cardiovascular events [23]. Pioglitazone
treatment was also shown to be associated with an increase
in heart failure although a significantly lower risk of myo-
cardial infarction and death was observed in this patient
population. Finally, muraglitazar an investigational drug
that is a dual agonist of PPARα and PPARγ was found to
be associated with an increase in major cardiovascular
events and increased incidence of death. The increases in
cardiovascular events and mortality seen with these drugs
are relatively small. Nevertheless, the wide scale use of
PPARγ agonists in the type II diabetic population has
raised serious concerns about the safety of these drugs for
long term therapy. The molecular basis underlying the in-
crease in cardiovascular events is not clear. Regulation of
the epithelial sodium channel (ENaCγ) in the kidney by
PPARγ has been suggested as potential mechanism respon-
sible for TZD-dependent edema but it remains to be seen
if inhibiting this channel will decrease the cardiovascular
events associated with TZD treatment. As the peroxisome
proliferator-activated receptors (PPARs) represent major
regulators of lipid metabolism in the liver, a few studies
have tested the hypothesis that genetic variants in these
hormone receptors may influence susceptibility to NAFLD,
but the results have been controversial [24-26]. As PPARs
are also the target of several drugs under evaluation for the
treatment of NAFLD, this evidence may lay the basis to de-
sign pharmacogenetic studies to assess the role of PPAR
SNPs in predicting the response to drugs targeting these
nuclear receptors.
Pex11a
Peroxisomes are organelles which have important roles
in cellular metabolism including very-long chain fatty
acid β-oxidation, cholesterol synthesis, and hydrogen
peroxide metabolism [27-29]. Peroxisome proliferation is
dependent on Pex11, which has been shown to promote
peroxoisome elongation in various model systems [30-34].
Three subtypes of Pex11 have been identified (α, β, and γ),
with Pex11α and γ being primary expressed in the liver
and Pex11β being more broadly expressed [34,35]. Weng
et al. [36] recently demonstrated that mice with Pex11α
knocked out had increased body weight and accumulated
fat in their livers. Pex11α knockout mice exhibited ele-
vated levels of free fatty acids without significant effects
on glucose or beta-hydroxybutyrate. While loss of Pex11α
impaired peroxisomal elongation, it also decreased the
expression of genes important for peroxisomal fatty acid
oxidation. Therefore, targeting peroxisomal function may
represent a new therapeutic target in the treatment of
NAFLD.
P53
P53 is well known to be a key regulatory of cellular me-
tabolism and has been shown to regulate the balance
between oxidative and glycolytic metabolism in cancer
cells [37]. Recently, p53 has also been implicated in
NAFLD largely through its role in regulating fatty acid
oxidation. Similar to its role in alcoholic fatty liver dis-
ease, p53 has been shown to be upregulated in the
livers of mice with NAFLD [38] and has been linked to
hepatocytes apoptosis in NAFLD [39]. To test the via-
bility of p53 as a therapeutic target in NAFLD, Derdak
et al. looked at the effect of a p53 inhibitor, pifithrin-
αp-nitro (PFT) on various parameters of NAFLD in a
murine model [40]. In HFD fed C57BL/6 mice, PFT treat-
ment was found to reduce hepatic steatosis, apoptosis,
and oxidative stress. These effects are believed to be sec-
ondary to a reduction in the upregulation of miRNA34a
and a shift toward high activity of the SIRT1/AMPK/ACC
pathway. SIRT1 increases the expression of AMPK which
blocks ACC allowing CPT1 to be activity due to reduced
levels of the inhibitory malonyl-CoA. In another arm of
the pathway, SIRT1 is also believed to upregulate PGC1α/
PPARα, which upregulates MLYCD subsequently de-
creasing MLYCD levels, decreasing Malonyl-CoA synthe-
sis and relieving the repression of CPT1. Another recent
study confirmed miR-34a upregulation and involvement of
SIRT1 and p53 in liver steatosis and found that treatment
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with ursodeoxycholic acid reversed p53 upregulation and
restored SIRT1 expression [41]. Taken together, these re-
sults support the role of p53 in regulating metabolism and
suggest that it may be a target for treatment of NAFLD.
Liver X receptor
The Liver X receptor (LXR) sub-group of the nuclear re-
ceptor superfamily is comprised of two sub-types, LXRα
and LXRβ that are encoded by separate genes. LXRα
was originally cloned from a liver cDNA library and
found to be highly expressed in the liver, kidney, and intes-
tine. In contrast, LXRβ is more ubiquitously expressed.
LXRs are important regulators of cholesterol and lipid me-
tabolism, and their activation has been shown to inhibit
cardiovascular disease and reduce atherosclerosis in ani-
mal models. More recent studies using knockout mice de-
ficient in the synthsis of oxysterols have provided strong
support that these cholesterol derivatives function as LXR
ligands in vivo [42]. The identification of hydroxycholes-
terols as natural LXR ligands prompted studies to identify
the genetic networks regulating cholesterol metabolism
which are controlled by LXR. An increase in hepatic chol-
esterol levels is predicted to lead to an elevation in the
concentration of cholesterol-derived LXR ligands resulting
in the catabolism of cholesterol to bile acid and the excre-
tion of cholesterol out of the liver. Indeed, when challenged
with a diet rich in cholesterol Lxrα−/− mice accumulate
massive amounts of cholesterol in the liver. In mice,
pharmacological activation of LXR has been shown to re-
sult in net movement of cholesterol out of the body, a
result consistent with the gene expression and genetic
knockout studies. In concert with the elimination of hep-
atic cholesterol, activation of LXR also decreases choles-
terol uptake by inducing expression of the Inducible
Degrader of the LDL receptor (Idol) [43]. Over expression
of Idol in cell culture models significantly enhances the
ubiquitination and proteosome-dependent degradation of
the LDL receptor. Additionally, Idol is expressed in macro-
phages where it may also affect cholesterol uptake.
Along with effects on cholesterol metabolism activa-
tion of LXR agonists also increases expression of genes
involved in fatty acid metabolism including the master
transcriptional regulator of fatty acid synthesis, sterol re-
sponse element binding protein 1c (SREBP1c) [1]. Sev-
eral of the genes encoding the enzymes involved in fatty
acid metabolism including fatty acid synthase (FAS) and
stearoyl CoA desaturase 1 (SCD-1) are directly or indir-
ectly regulated by LXR. The up-regulation of fatty acid
synthesis in coordination with reverse cholesterol trans-
port is most likely to provide lipids for the transport and
storage of cholesterol. Small molecule agonists of LXR
activity are therefore of great therapeutic interest. Never-
theless, the elevations in plasma cholesterol and trigly-
ceride levels seen in LXR agonist-treated animals have
severely limited the potential transition of the first gen-
eration LXR agonists into the clinic. However, the find-
ing that such agonists also promote hepatic lipogenesis
has led to the idea that hepatic LXR activity may be un-
desirable from a therapeutic perspective. Liver-specific
deletion of LXR eliminated the detrimental effect of in-
creased plasma triglycerides, while the beneficial effect
of increased plasma HDL was unaltered.
There are numerous studies that have reported LXR
plays a major role in the regulation of macrophage reverse
cholesterol transportation (RCT) and that will contribute
to the lipid accumulation in the liver and development of
atherosclerosis. The Liver X Receptors (LXRs) α and β and
the Peroxisome Proliferator-Activated Receptor α (PPARα)
are transcription factors that belong to class II nuclear re-
ceptors. They drive the expression of genes involved in
hepatic lipid homeostasis and therefore are important tar-
gets for the prevention and treatment of nonalcoholic fatty
liver disease (NAFLD). LXRs and PPARα are regulated by
endogenous ligands, oxysterols and fatty acid derived mol-
ecules. In the liver, pharmacological activation of LXRs
leads to the over-expression of genes involved in de novo
lipogenesis, while activation of PPARα is critical for fatty
acid catabolism in nutrient deprivation. While these two
nuclear receptors appear to have opposing effects, recent
studies have highlighted that PPARα also influences
the expression of genes involved in fatty acids synthesis.
T0901317 and fenofibrate induce expression of genes in-
volved inLXR-dependent and PPARα-dependent lipogenic
responses. Deficiency of PPARα does not influence the ef-
fects of T0901317 on lipogenic genes expression. However,
PPARα deficiency prevents the up-regulation of genes in-
volved in ω-hydroxylation that are induced by T0901317.
In addition, over-expression of lipogenic genes in response
to fenofibrate is decreased in LXR knockout mice as well
as the expression of PPARα target genes involved in fatty
acid oxidation. This supports the existence of an inter-
action between these nuclear receptors and suggests LXR
and PPARα may have overlapping control over the expres-
sion of hepatic genes involved in lipid metabolism.
Thyroid hormone receptor
The antiobesity and low-density lipoprotein (LDL)–chol-
esterol–lowering effects of thyroid hormones have been
known for years, but their pharmacological use has been
limited by their untoward effects on bone and heart and
skeletal muscle. Recent research has developed compounds
that lack these adverse effects while harnessing the benefi-
cial effects of thyroid hormone. The development of these
drugs, termed thyromimetics, was made possible by the
existence of distinct thyroid hormone receptor (TR) sub-
types with different tissue-specific distributions [44]. The
two subtypes of TRs, TRα and TRβ, are predominantly lo-
calized in the heart and liver, respectively. Selective TRβ1
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agonists have been synthesized and evaluated in preclinical
trials and in a small clinical trial, demonstrating their lipid-
lowering properties and safety [45]. The liver specificity
of these drugs is achieved through the selective hepatic
distribution of phosphonic acid: which is phosphonate-
containing TRβ1 agonist that is taken up predominantly
by the liver with a high first pass extraction and con-
verted into the active form in hepatic microsomes by
cytochrome P450 3A. Recently, the main compound of
this type, MB07811, has been evaluated in different ani-
mal models of hepatic steatosis, including ob/ob mice,
Zucker diabetic rats, and mice with diet-induced obesity
[46]. A marked reduction was observed in plasma choles-
terol and triglyceride levels. Hepatic selectivity of MB07811
was demonstrated by showing that this agent did not affect
circulating FFA levels, epidydimal fat pad and heart mass,
or pituitary thyroid-stimulating hormone mRNA. A de-
crease in hepatic lipogenesis, as suggested by a reduction
in SREBP-1c mRNA, and in hepatic lipase activity, as sug-
gested by reduced levels of apolipoprotein C3 (apo C3, an
inhibitor of lipoprotein lipase), might also contribute to the
antisteatotic effects of this agent. GC-1, another TRβ1-
selective activator, ameliorated not only steatosis but also
markers of hepatic lipoperoxidation and liver injury, sug-
gesting these agents have the potential to reverse not only
fat infiltration but also the progressive features of steato-
hepatitis. How TR mimetics can ameliorate hepatocyte
oxidative stress and necroinflammation warrants further
investigation. These futile cycles reduce oxidative stress
in two ways: they increase ATP cycling, which enhances
oxidative phosphorylation and decreases the formation
of reactive oxygen species (ROS); and they supply the
NADPH necessary for the regeneration of reduced gluta-
thione (GSH) and other reducing substances, thus facilitat-
ing the scavenging of ROS [47]. Collectively, the results of
the studies show promise for the treatment of NAFLD and
associated metabolic disorders, but efficacy and safety of
this class of agents in humans need further evaluation.
AMP-activated protein kinanse (AMPK)
As discussed in previous sections, signaling through AMP
can have a beneficial effect on hepatic steatosis. AMPK
has emerged as a central regulator of cellular metabolism.
AMPK consists of heteromeric complexes with a catalytic
α subunit and regulatory β and γ subunits. AMPK is able
to sense the energy status of the cell in a variety of differ-
ent ways. The γ subunits are able to bind adenine nucleo-
tides, with ADP and AMP leading to activation of AMPK
though allosteric activation and phosphorylation [48].
AMPK is able to regulate metabolism through its effects
on glucose homeostasis, lipid metabolism, protein synthe-
sis, and oxidative metabolism. AMPK exerts its control
over glucose metabolism at a number of different steps in
glucose utilization. AMPK promotes the upregulation of
the proteins needed for glucose uptake into cells [49],
phosphorylates 6-phosphofructo-2-kinase (PFK-2) thereby
upregulating glycolysis [50], inhibiting gluconeogenesis
though multiple mechanisms [51], and phosphorylating
and inhibiting glycogen synthase and subsequently redu-
cing the amount of glycogen synthesized [52]. AMPK is
able to control lipid metabolism by both decreasing lipo-
genesis and stimulating mitochondrial fatty acid oxidation.
The former task is accomplished by phosphorylating 3-
hydroxy-3-methylglutaryl-coenzyme A reducase (HMG-
CoA) and acetyl CoA carboxylase 1 (ACC1). Inactivation
of HMG-CoA reducase blocks the conversion of HMG-
CoA to mevalonate and inactivation of ACC1 results
in decreased ability to synthesize fatty acids. AMPK’s
ability to promote fatty acid oxidation is attributed to
decreased synthesis of malonyl CoA due to phosphoryl-
ation of ACC2 which relieves the inhibition of carnitine
O-palmitoyltransferase 1 (CPT1). Recently, AMPK has
also been shown to phosphorylate the transcriptional
co-activator transducer of regulated CREB activity 2
(TORC2), excluding it from the nucleus and decreasing
transcription of the gluconeogenic genes PEPCK and
glucose-6-phosphatase [53]. Importantly, AMPK has also
been shown to decrease transcription of lipogenic genes
thought its inhibition of sterol regulatory element-binding
protein-1c (SREBP1c) [54]. Additionally, AMPK has been
shown to upregulate oxidative phosphorylation through
its ability to positively regulate PGC-1α through phos-
phorylation, which subsequently increases mitochondrial
biogenesis [55].
Given its ability to sense and regulate the metabolic
state of the cell, modulation of AMPK has become an
important therapeutic target in NAFLD. Exercise has
well known beneficial effects in the metabolic syndrome
as well as in NAFLD and some of these effects may be
due to its modulation of the AMPK signaling pathway as
expression of genes induced by exercise requires AMPK
activation [56,57]. Various compounds already in use for
the treatment of type 2 diabetes have been shown to
have effects on the AMPK pathway. The beneficial effects
of thiazolidinediones on hepatic steatosis were discussed
above with activation of PPARα as a driving mechanism.
However, the thiazolidinediones have also been shown to
increase the AMPK signaling pathway with improvement
in both hepatic steatosis and fibrosis [58]. Additionally,
biguanides such as metformin have been shown to induce
AMPK activity in hepatocytes subsequently increasing
fatty acid oxidation, decreasing lipogenesis, and decreasing
hepatic glucose production [59]. Treatment with metfor-
min has been shown to reverse liver steatosis and its lipid
lower effects were shown to be dependent on AMPK acti-
vation [60]. The mechanism by which AMPK is induced
by both of these classes of drugs likely involves alteration
of mitochondrial function. Thiazolidinediones bind to and
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impair assembly of complex I [61] as well as impair-
ing mitochdrial pyruvate transport [62] and metformin
has been shown to inhibit mitochondrial complex I
thus decreasing the ATP to ADP/AMP ratio and indu-
cing AMPK.
Polyphenols such as resveratrol [63] and epigallocate-
chin gallate [64] have been demonstrated to activate
AMPK. One suggested mechanism has been the ability
of these compounds to activate sirtuin 1 (SIRT1), which
acts as a metabolic regulatory through its ability to sense
NAD+ levels and also is an upstream regulator of AMPK
[65]. Epigallocatechin gallate’s may also increase reactive
oxygen species production, and subsequently activate
CaMKK which can phosphorylate AMPK [66]. However,
these compounds also likely act through their effects on
adenine nucleotide levels as resveratrol has been shown to
inhibit mitochondrial complex V [67] and epigallacatechin
gallate has been shown to inhibit mitochondrial complexes
I, II, and V [68].
5-aminoimidazole-4-carboxamide-1-b-d-ribofuranoside
(AICAR) has been extensively demonstrated to activate
hepatic AMPK activity. Treatment with AICAR has been
shown to decease hepatic lipid accumulation through
AMPK activation [69] and also decrease hepatic glucose
production largely through TORC2 inactivation as well
as increasing skeletal muscle glucose uptake [70]. While
AICAR’s effects on AMPK is due to allosteric activation
by its metabolite 5-aminoimidazole-4-carboxamide ribo-
tide (ZMP) which is structurally similar to 5’-AMP, it was
originally believed that AICAR treatment did not affect
endogenous adenine nucleotide levels. However, recent
studies have shown that AICAR treatment results in ATP
depletion [71] and can impair mitochondrial function
[72], potentially limiting its therapeutic use.
More recently, other activators of AMPK have been
discovered after screening chemical libraries. A-769662 has
been found to increase AMPK activity through allosteric
activation as well as inhibition of dephosphorylation [73].
Furthermore, A-769662 treatment did not alter adenine
nucleotide levels nor affect mitochondrial function [74].
Betaine is a metabolite of choline and has previously
been shown to be beneficial in alcoholic liver disease.
Given its ability to activate AMPK [75], it has also been
sought as a treatment for NAFLD. Indeed, an initial pilot
study reported beneficial effects of betaine treatment on
various parameters of liver function including reduced
steatosis and fibrosis.
α-Lipoic acid has been shown increase glucose uptake
by skeletal muscle and also to activate AMPK in resulting
in increased fatty acid oxidation in skeletal muscle [76].
Additionally, part of α-Lipoic acid’s beneficial effects may
be due to activation of PPARα and FGF21 [77].
AMPK is also modulated by hormones and cyto-
kines such as resistin, leptin, adiponectin, and ghrelin
[53]. The ability of adiponectin to lower hepatic glucose
production has been attributed to activation of AMPK
[78], as adiponectin was unable to regulate hepatic glu-
cose production in AMPKα2 mice [79]. Adiponectin has
been shown to decrease hepatic triglyceride content and
thereby restore insulin sensitivity and decrease hepatic
fat deposition [80].
Bile-acid receptor and TGR5
Bile acids (BAs) are critical regulators of hepatic lipid
and glucose metabolism and signal through two major
receptor pathways: FXR (as discussed above) and TGR5,
the G protein-coupled bile acid receptor (GPBAR1).
Both FXR and TGR5 demonstrate pleiotropic functions
including immune modulation. The activation of BA re-
ceptors modulates hepatic monocyte activity and im-
proves non-alcoholic fatty liver disease. McMahanet al
[81] reported that obese db/db mice were treated with a
dual FXR/TGR5 agonist (INT-767) for 6 weeks and the
histologic features of NASH in these mice were significantly
improved. Furthermore, treatment increased the proportion
of intrahepatic monocytes with the anti-inflammatory
Ly6Clow phenotype and increased intrahepatic expression
of genes expressed by alternatively activated macrophages.
In vitro treatment of monocytes with INT-767 led to de-
creased Ly6C expression and increased IL-10 production
through a cAMP-dependent pathway. This indicates that
FXR/TGR5 activation may be an important therapeutic
target in NAFLD by coordinating the immune phenotype
of both monocytes and macrophages.
Nrf2
Nuclear erythroid 2-related factor 2 (Nrf2) is an oxida-
tive stress-mediated transcription factor with a variety of
downstream targets aimed at cytoprotection. Nrf2 has
recently been implicated as a new therapeutic target for
the treatment of liver disease. Lipid peroxidation has been
shown to impair nucleotide and protein synthesis, thereby
inducing apoptosis, inflammation, and liver fibrosis. It has
been proposed that Nrf2 plays a role in NASH because
genetic deletion of Nrf2 in mice results in rapid onset and
progression of the disease. There are several stages of dis-
ease pathogenesis on which activation of Nrf2 may exert a
potential therapeutic effect. The first is in the initial stages
of the disease, when lipids are accumulating within the he-
patocytes. Nrf2 activation with CDDO-Im has been shown
to effectively prevent hepatic lipid accumulation in wild-
type mice but not in Nrf2- deficient mice, an effect that
may be mediated by a decrease in expression of enzymes
required for fatty acid synthesis. Nrf2 may also protect
against NAFLD by decreasing inflammation. Several che-
motherapeutic agents have been shown in a variety of cell
culture and rodent systems to induce Nrf2 and cause
simultaneous repression of nuclear factor-κB (NF-κB),
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an important cell-signaling molecule for the inflammatory
response. Additionally, pharmacological activation of Nrf2
results in increased gene expression of Heme oxygenase 1
(Ho-1) and NAD(P)H quinone oxidoreductase 1 (Nqo1),
which in turn have inhibitory effects on inflammation [82].
Ho-1 has been shown in mice to prevent phosphorylation
of NF-κB by its endogenous substrate tumor necrosis
factor-α, 61 indicating that it has inhibitory effects upstream
on the initiation of the inflammatory response. Under
normal conditions, lipopolysaccharide(LPS) can be used to
induce the expression of tumor necrosis factor-α and cause
inflammation through activation of NF- κB, however,
Nqo1 and Ho-1 overexpression, such as occurs with Nrf2
activation, has been shown in human monocytes to pre-
vent the LPS mediated induction of tumor necrosis factor-
α expression, thereby preventing inflammation. Another
mechanism for the potential treatment of NAFLD and
NASH is through activation of superoxide dismutase and
catalase, antioxidant enzymes with decreased activity in
this disease state. The pharmaceutical agent and Nrf2 acti-
vator Protandim has been shown in human trials to in-
crease erythrocyte superoxide dismutase and catalase
activity by 30 and 54%, respectively. Finally, it is possible
that activation of Nrf2 could play an inhibitory role on
transforming growth factor-β (TGF-β), a profibrotic signal-
ing factor in plasma, and therefore may inhibit the progres-
sion of fibrosis in NASH. A recent study demonstrated
that sulforaphane attenuates hepatic fibrosis through Nrf2-
mediated inhibition of TGFβ signaling in a human hepatic
stellate cell line. This effect was ultimately due to the sup-
pression of hepatic stellate cell activation and fibrogenic
gene expression, indicating that activation of Nrf2 has an
antifibrotic effect in liver. These findings support a role
for Nrf2 signaling in various steps of the pathogenesis
of NAFLD.
Mitochondria
Given their central role in metabolism and fatty acid
homeostasis, much attention has recently been focused
on the role of mitochondrial function in NAFLD and
NASH. However, the exact role of mitochondrial func-
tion remains far from clear, and several studies have
yielded conflicting results. While a detailed over of all of
the studies on the topic is beyond the scope of this re-
view and has been reviewed in detail elsewhere [83-85],
we will present a brief overview here. In healthy individ-
uals, lipid uptake and synthesis is relatively well balanced
with fatty acid oxidation and lipid export as VLDL being
matched by lipid synthesis and lipid uptake [86]. How-
ever, insulin resistance and hyperglycemia lead both to
increased lipolysis in white adipose tissue which in-
creases the serum fatty acid concentration as well as in-
creased lipid synthesis and uptake by the liver resulting
in fat accumulation [87]. Liver mitochondria exhibit the
ability to adapt to these changing metabolic conditions
and the majority of studies indicate that in various states
of disease progression, mitochondria are able to increase
fatty acid oxidation in an attempt to counteract liver fat
accumulation [88-90]. Various mechanisms underlie this
increase in fatty acid oxidation including higher levels of
leptin [91], FGF21 [92,93], and IL-6 [94]. PPARα activa-
tion has also been demonstrated [95,96] and can upregu-
late several genes involved in fatty acid oxidation
namely CPT1 [97]. While fatty acid oxidation is able to be
upregulated, most of the available evidence has shown that
ATP levels are lower in patients with NASH as well as in
animal models [98] even though a number of studies have
demonstrated that overall oxygen consumption is either
increased [99] or unchanged [100]. These seemingly para-
doxical results may be due to increased expression of
UCP2 in NAFLD resulting in mitochondrial uncoupling
[101]. This may well represent a potentially adaptive
mechanism to limit reactive oxygen species production
which would be presumably induced by the influx of redu-
cing equivalents from increased fatty acid oxidation [102].
However, this mechanism is seemingly insufficient to pro-
tect mitochondria from free radical mediated damage as
impaired enzymatic activity of various complexes of the
electron transport chain has been repeatedly demonstrated
[103,104]. Several electron transport chain complexes have
been shown to be susceptible to inhibition by ROS. ROS
can also led to lipid peroxidation which can induce dys-
function of complex IV and the adenine nucleotide translo-
cator as well as altering mitochondrial DNA [105]. Indeed,
as increased fatty acid oxidation results in more ROS pro-
duction and damage to the electron transport chain, a fur-
ther mismatch between the two likely occurs presumably
resulting in progressively more electrons being lost as free
radicals [102].
Therapeutic strategies to target mitochondria as treat-
ments for NAFLD and NASH are still in the very early
stages. Approaches to further increase fatty acid oxida-
tion have been proposed in order to decrease the accu-
mulation of fat in the liver [106], however this approach
may further exacerbate the imbalance between fatty acid
oxidation and the electron transport chain further in-
creasing ROS production. To this point, inhibition of
CPT-I, which catalyzes the rate-limiting step of fatty acid
oxidation, has been shown to prevent high fat diet in-
duced insulin resistance, in part due to a reduction in
some of the deleterious intermediates generated by in-
complete fatty acid oxidation and also due to a shift to-
ward increased glucose oxidation for energy production
[107]. Therefore, the development of viable therapeutics
targeting mitochondrial pathways will likely be more
complicated than anticipated and should take into account
not only the effect on the liver but also potential effect
on the metabolic pathways of other tissues. Nevertheless,
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some compounds shown to improve mitochondrial func-
tion have shown initial promise in treating NAFLD.
Curcumin, which is known to have hepatoprotective
effects, was shown to inhibit the progression of hepatic
steatosis in a rabbit model by improving mitochondrial
respiratory chain function, decreasing oxidative stress,
and reducing levels of TNF-α [108]. Similarly, silybin,
which has antioxidant, anti-inflammatory, and anti-fibrotic
activity, has been shown to protect against oxidative stress,
preserve mitochondrial function, and limit the pro-
gression of NASH in an animal model [109]. Given their
already widespread use and minimal side effect profile,
other antioxidants such as vitamin E, vitamin C, and N-
acetylcysteine have been studied in models of NASH with
favorable outcomes [110]. While extensive clinical data
demonstrating the beneficial effect of antioxidants in
NASH remain to be generated, early studies have shown
promise. For instance, a silybin-vitamin E compound has
been shown to improve various parameters of liver func-
tion in patients with NAFLD.
Cannabinoid receptors
Cannabinoids exert their effects through two different
cannabinoid receptors: CB1 and CB2, both of which are
G-protein coupled. Both of these receptors have been
implicated in the development of liver fibrosis secondary
to various etiologies. It has been shown that marijuana use
may correlate with the progression of liver fibrosis in pa-
tients with hepatitis C [111]. However, each receptor seems
to have opposing roles in the liver. The rCB2 recepto has
been shown to be up-regulated in the livers of cirrhotic pa-
tients and has been shown to ameliorate the progression of
fibrosis [112]. In contrast, CB1 receptor activation has been
linked to the progression of fibrosis and CB1 antagonists
have been shown to inhibit the progression of fibrosis
[113]. Indeed, clinical trials with a CB1 receptor antagonist
have shown that antagonism of CB1 can result in weight
loss and improved metabolic and cardiac parameters in
overweight and obese populations [114]. However, given
considerable side effects, future compounds developed for
the treatment of NASH will likely need to be peripherally
targeted [115].
Cannabinoid receptors are have emerged as major tar-
gets for the treatment of obesity. New compounds which
target cannabinoid receptors have been developed for
weight loss and may prove to be efficacious in the manage-
ment of NAFLD. Experimental and clinical data indicate
that peripheral activation of cannabinoid CB1 receptors
promotes insulin resistance and liver steatogenesis, two
key steps in the pathogenesis of non-alcoholic fatty liver
disease. Moreover, activation of CB1 receptorsenhance
progression of liver fibrogenesis. These findings provide
the rationale for the use of CB1 antagonists in the manage-
ment of NAFLD or NASH.
Conclusions
In this review, we have outlined some of the molecular
pathways contributing to the pathogenesis of NAFLD.
While the details of many of these pathways are still be-
ing elucidated, they provide targets for future thera-
peutic strategies in NAFLD. Still, much work remains to
be done in detailing the exact mechanisms contributing
to NALD and the coordination and interaction among
the various pathways that have already been implicated
in disease pathogenesis.
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